BPC-157 side effects: what has been reported and what nobody has measured

Nobody knows the true side effect profile of BPC-157, and that is the honest headline. Drug labels list side effects because large trials counted them against placebo. BPC-157 has no such trial, so there are no rates to report. FDA concluded in 2026 that there is “insufficient clinical safety information to characterize the safety profile.” A clean-looking record here mostly reflects how little anyone has looked, and “no reports” should not be read as “no risk.”

What has been reported

Here is every human source we could find, with what each can and cannot tell you. Clinical trials would give you percentages. These do not.

AJMC also reported that FDA’s database has logged 10 serious adverse event reports tied to BPC-157 since 2021, 8 of them in 2026, though such reports do not establish cause. FDA notes that 503A compounders generally do not report adverse events to it, so any count is a floor. The interim HHS policy makes serious-event reporting one of its conditions for tolerated compounding, which may change the numbers.

The skin and gum darkening case

One FDA report stands out, because the reaction repeated. A 40-year-old woman injected a BPC-157 and TB-500 product labeled for research purposes, twice a day. After about a week she developed widespread darkening of her skin and gums. Two weeks later she used it again and the same thing happened, and it stopped when she quit. FDA said the product was the likely cause, but with two peptides in the vial it could not say which one. That is exactly the problem HHS gave for limiting tolerated compounding to single-ingredient products.

When do side effects start, and do they fade?

Nobody can say for BPC-157 in general, because no study has tracked this. In the handful of reports, the injection-site reaction lasted 9 days and the skin darkening began within a week. Safety has not been measured systematically beyond a few weeks in people, so late effects are an open question.

What animal studies flagged

A single published toxicology paper (Xu et al. 2020) gave BPC-157 by injection into muscle to rats and dogs for 28 days. Its authors called the changes they found incidental. FDA was more cautious and said some appeared to be “clinically relevant safety signals.”

These findings have not been tested in people. On the reassuring side, the same paper found no sign that BPC-157 damages DNA and no birth defects in a rat study, though no one has studied a full reproductive cycle. FDA found no toxicology at all for the oral, under-the-skin or nasal routes.

Concerns that are still theoretical

Everything in this section is a published concern. None has been observed as harm in people.

Immune reactions. This is FDA’s main worry for injected BPC-157. The body can make antibodies against a peptide, and peptides can clump together (aggregate), which makes that more likely. FDA says outcomes range from nothing noticeable to “life-threatening and catastrophic reactions,” and that they are hard to predict. No study has formally tested this for BPC-157. FDA rated the inherent immune risk of oral BPC-157 as likely low.

Cancer. FDA found no carcinogenicity studies, so the question has simply not been tested. The concern is indirect. BPC-157 is proposed to encourage new blood vessels, and a 2025 narrative review noted that abnormal blood vessel growth is involved in tumor growth. The same review cited preclinical work pointing the other way, and BPC-157’s long-time researchers reject the concern. Neither side has human data.

Other proposed effects. That 2025 review also raised possible problems from strong stimulation of nitric oxide and from a breakdown product, proline. It framed these as hypotheses drawn from other research. It concluded that BPC-157 should not be recommended for clinical use in musculoskeletal medicine until well-designed trials exist.

The risks of unregulated injections

Many real-world risks come from the product and the needle, whatever the peptide does.

• Unknown contents. Vials sold for “research use only” are not legal to use on people. HHS itself says such peptides from foreign manufacturers “pose a safety risk to US patients,” and it names endotoxins, heavy metals, microbial contamination and impurities as the contaminants its testing conditions are meant to catch.
• Label versus contents. After emergency visits linked to peptides surged in New South Wales, Australia, to 1,180 between July 2025 and September 2026, the Chief Health Officer warned that a purity claim “is not proof of what is inside the product.” Clinicians there reported kidney damage and liver injury. In the underlying report, 71% of those visits mentioned retatrutide only, so they say little that is specific to BPC-157.
• Dosing mistakes. Mixing a powder and reading a syringe leaves room for large errors. The BPC-157 dosage page lists the common ones.
• Infection. Any injection can introduce bacteria into the skin.
• Compounded products are not risk-free. FDA does not review them, and it warned that formulation, concentration and storage can create impurities and aggregates.

What helps if you get a reaction?

There is no tested remedy for a BPC-157 reaction, because no one has studied one. In the case above the reaction stopped when the woman quit. If you do see a clinician, bring the vial or label, since knowing exactly what you took and how much is the first thing they will need. The are peptides safe guide covers the wider picture.

Red flags: when to get help

No BPC-157 label exists to give specific warnings, so these come from general medical guidance on allergic reactions and skin infections, which apply to any injection.

How to report a problem

FDA’s MedWatch program takes reports from consumers and clinicians online. Reporting matters more than usual here: with no trials, these reports are close to the only human safety data that exist, and HHS says it may revisit its policy if a safety signal appears. A 2026 systematic review put it plainly, rating the certainty of human evidence very low and saying BPC-157 should not be used clinically outside regulated trials.